Novartis | NVS - Stock


Novartis reported $6.42B in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Amgen USD 6.19B 39M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
Bausch Health Companies USD 1.63B 31M Dec/2025
Biogen USD 1.95B 219.1M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Canopy Growth CAD 105.56M 3.18M Dec/2025
Corcept Therapeutics USD 12.89M 22K Mar/2026
Drreddys Laboratories INR 79.01B 3.41B Dec/2025
Eli Lilly USD 14.53B 785M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
J&J USD 14.58B 392M Mar/2026
Merck USD 6.48B 179M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Novartis USD 6.42B 114M Sep/2025
Pacira USD 150.37M 2.49M Mar/2026
Perrigo USD 1.12B 27.6M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Phibro Animal Health USD 539.7M 22.35M Mar/2026
Prestige Brands USD 159.13M 4.46M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Supernus Pharmaceuticals USD 110.77M 1.71M Mar/2026
Zoetis USD 2.55B 120M Mar/2026